RxDoctor Payments Data

Bridget Mashburn

Family · Johnson City, TNNPI 1982210928

Payments from drug & device makers

$1,875in general payments, 2019–2025

Across 113 payments — averaging $16.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$481
  • GSK$242
  • Lilly USA, LLC$195
  • Boehringer Ingelheim$137
  • Scynexis, Inc.$94
  • AstraZeneca$81
  • plus $645 from 19 others

What the payments were for

  • Food & beverage$1,875100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,875 in reported general payments places this provider in the 75th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$20,323
Medicare patients
56
Services billed
697

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin38$31,856
OzempicSemaglutide18$30,175
EliquisApixaban28$25,972
VraylarCariprazine Hcl12$20,116
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$19,896
Bevespi AerosphereGlycopyrrolate/Formoterol Fum24$10,507
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$10,169
Omeprazole66$1,508
Gabapentin73$1,327
Fenofibrate12$845
Levothyroxine Sodium71$805
Lisinopril94$738
Pravastatin Sodium70$683
Fluticasone Propionate26$664
Albuterol Sulfate HfaAlbuterol Sulfate37$641

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$137$31,85638 claims
Novo NordiskOzempic$64$30,17518 claims
GSKTrelegy Ellipta, Anoro Ellipta$242$30,06541 claims
PfizerEliquis$38$25,97228 claims
AbbVieVraylar$481$20,11612 claims
AstraZenecaBevespi Aerosphere$81$10,50724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,706 family providers in Tennessee.

Other family in Johnson City

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →